Full Press Release Details
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update.
IDYA
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Key Takeaway: IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Price reaction · baseline $33.19 (2026-03-06 close) · clean, no other IDYA news in the window
day 0 close · peak
+5.7%
day 1
+4.7%
day 3
-1.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma